"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
| Descriptor ID |
D018033
|
| MeSH Number(s) |
D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
|
| Concept/Terms |
Antibodies, Bispecific- Antibodies, Bispecific
- Bispecific Antibodies
- Bifunctional Antibodies
- Antibodies, Bifunctional
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".
This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2017 | 12 | 1 | 13 |
| 2018 | 14 | 3 | 17 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 2 | 3 |
| 2021 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Haemophilia. 2021 Sep; 27(5):736-743.
-
Evaluating a new mixed-mode resin Diamond MMC Mustang using Capto MMC ImpRes as a benchmark. Protein Expr Purif. 2021 10; 186:105930.
-
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res. 2021 05 28; 128(11):1780-1801.
-
Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit. Haemophilia. 2021 Jul; 27(4):e567-e570.
-
Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia. Hamostaseologie. 2021 Jun; 41(3):190-196.
-
Preparing for the Future - Nanobodies for Covid-19? N Engl J Med. 2021 Apr 22; 384(16):1568-1571.
-
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021 05; 593(7859):424-428.
-
Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer. Int J Mol Sci. 2021 Feb 28; 22(5).
-
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2. MAbs. 2021 Jan-Dec; 13(1):1893426.
-
Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. Emerg Microbes Infect. 2020 Dec; 9(1):1034-1036.